newsfilter
← Latest News
GlobeNewswire·

Kinnate Biopharma Inc. Reports First Quarter 2023 Financial Results and Recent Corporate Updates

Presented positive monotherapy dose escalation data for exarafenib, an investigational pan-RAF inhibitor, at the 2023 AACR Annual Meeting Provided update on ongoing exarafenib monotherapy dose expansion; data-informed